BioNTech SE (22UA) AI Stock Analysis

63 Followers

BioNTech SE

(XETRA:22UA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Balance-sheet strengthBioNTech’s substantial liquidity and minimal leverage provide financial resilience while the company funds a costly oncology transition. This balance-sheet flexibility can support pivotal trials, partnerships, corporate development and shareholder returns without relying heavily on debt.

Negative Factors

Declining vaccine-linked revenueLower COVID-19 demand continues to pressure BioNTech’s largest historical revenue stream as the market shifts from pandemic procurement toward seasonal vaccination. This creates a durable transition risk until oncology products and partnerships generate more recurring revenue.

BioNTech SE (22UA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 21.99B
Dividend Yield: ―
Average Volume (3M): 37.63K
Price to Earnings (P/E): -11.8
Beta (1Y): 0.86
Revenue Growth: -7.93%
EPS Growth: -370.76%
Country: Germany
Employees: 7,807
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which fe...

BioNTech SE Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:-0.06%|Next Earnings Date:May 11, 2020

Earnings Call SentimentPositive

The call was broadly optimistic, supported by strong gotistobart survival data, encouraging pumitamig combination results, a growing late-stage pipeline, a substantial cash balance, and a raised revenue-guidance midpoint. However, the company also reported lower COVID-19-related revenue, higher R&D and SG&A expenses, discontinuation of the colorectal cancer trial, a missed progression-free survival endpoint for BNT113, and limitations and safety concerns around T-Pam. The highlights significantly outweighed the lowlights, although several clinical programs remain subject to upcoming readouts and development decisions.

Positive Updates

Gotistobart Nearly Doubled Median Overall Survival

In the non-pivotal stage of the global phase III trial in metastatic squamous non-small cell lung cancer after prior checkpoint inhibitor treatment, gotistobart produced median overall survival of 18.5 months versus 10 months with docetaxel, with a hazard ratio of 0.56 and a 44% reduction in the risk of death compared with chemotherapy. The pivotal stage is ongoing, with an interim analysis anticipated before year-end.

Negative Updates

Third-Quarter Revenue Decline

Third-quarter 2026 revenue was EUR 1.3 billion versus EUR 1.5 billion in the prior-year quarter. The decline mainly reflected anticipated lower market demand for BioNTech's COVID-19 vaccine.

Company Guidance

BioNTech raised its full year 2026 revenue guidance to EUR 1.7 billion to EUR 1.9 billion, while maintaining adjusted R&D expense guidance of EUR 2 billion to EUR 2.3 billion and adjusted SG&A expense guidance of EUR 700 million to EUR 800 million; it expects the first interim analysis for gotistobart in squamous non-small cell lung cancer before year-end, a second one next year, first trials for pumitamig and Alpha-D novel combinations to begin in 2027, first-line TNBC in China data in 2027, ROSETTA Lung-02 and ROSETTA Lung-01 around 2029, and readouts for RCC, CRC, HCC, and the other studies thereafter, while it has seven global pivotal studies ongoing by end of this year and remains on track to become a diversified multi-product company by 2030.

BioNTech SE Risk Analysis

BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.666Annual Report on FormQ4, 2024

BioNTech SE Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:22UA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	83Outperform	$25.57B	19.89	20.18%	―	2.49%	9.29%
GMAB	71Outperform	$33.22B	43.72	13.58%	―	21.75%	-36.69%
INCY	68Neutral	$24.47B	55.99	7.11%	―	24.88%	-65.67%
MRNA	55Neutral	$88.16B	-28.63	-39.20%	―	-27.62%	-6.22%
ROIV	54Neutral	$25.92B	-94.84	-6.12%	―	-67.58%	45.61%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:22UA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:22UA	Biontech Se Sponsored Adr	78.10	-13.05	-14.32%
INCY	Incyte	117.59	11.89	11.25%
UTHR	United Therapeutics Corp.	601.32	153.87	34.39%
GMAB	Genmab (Otc)	55.52	26.33	90.20%
MRNA	Moderna	228.44	204.88	869.61%
ROIV	Roivant Sciences Ltd.	36.04	15.81	78.15%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BioNTech SE AI Stock Analysis